Methylin Chewable Tablets Return To Market For ADHD
This article was originally published in The Pink Sheet Daily
Alliant Pharmaceuticals has returned the only chewable tablet for the treatment of attention deficit/hyperactivity disorder in children to the market. The company announced the availability of Methylin (methylphenidate) tablets June 6
You may also be interested in...
Alliant widens its voluntary recall of Methylin CT tablets from one 2,280-bottle lot of 5 mg product to 11 lots of 2.5 mg, 5 mg and 10 mg strengths, encompassing approximately 10,000 bottles. The company is asking pharmacists to notify patients of the recall.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.